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OBJECTIVE— Reduction in LDL and high sensitivity (hs) C-reactive protein (CRP) are
independent indicators of successful cardiovascular risk reduction with statins. This study com-
pared the effect of equivalent LDL-lowering doses of simvastatin and atorvastatin on hsCRP in
type 2 diabetic patients.
RESEARCHDESIGNANDMETHODS— A crossover study of 26 patients with type 2
diabetes taking either 40 mg simvastatin or 10 mg atorvastatin was undertaken. After 3 months
on one statin, lipids and hsCRP were measured on 10 occasions over a 5-week period. The same
procedure was then followed taking the other statin.
RESULTS— LDL was comparable on either treatment: atorvastatin 2.2  0.2 vs. 2.1  0.3
mmol/l (mean  SD; P  0.19). CRP of individuals taking atorvastatin was significantly lower
than when they were taking simvastatin (median 1.08 vs. 1.47 mg/l, P  0.0002) and was less
variable (median SD of logCRP 0.0036 vs. 0.178, P  0.0001).
CONCLUSIONS— Compared with simvastatin, atorvastatin reduced hsCRP and its vari-
ability in type 2 diabetic patients. This enhanced anti-inflammatory effect may prove beneficial
if lower CRP is associated with improved cardiovascular risk.
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The ability of high sensitivity (hs) C-reactive protein (CRP) to predictcardiovascular risk has been con-
firmed in diverse population cohorts in-
cluding type 2 diabetic patients (1).
Patients who have lower hsCRP levels af-
ter statin therapy have better clinical out-
comes regardless of the resultant level of
LDL (2,3). Reduction in LDL and hsCRP
are independent indicators of the success
of statins in reducing cardiovascular risk
(4). To assess any difference between the
effect of long and short half-life statins on
hsCRP and its variability, we conducted a
crossover study with equivalent lipid-
lowering doses of simvastatin and
atorvastatin.
RESEARCH DESIGN AND
METHODS— All subjects gave their
informed consent, which had been ap-
proved by the Research Ethics Commit-
tee. A total of 30 consecutive Caucasian
patients with type 2 diabetes and A1C be-
tween 6 and 9% were recruited. There
were 19 patients taking 10 mg atorvasta-
tin and 11 patients on 40 mg simvastatin
before bed. The biological variation of
hsCRP was assessed by measuring fasting
blood samples at 4-day intervals on 10
consecutive occasions. Thereafter, the pa-
tients on simvastatin were changed to the
equivalent dose of atorvastatin and vice
versa (5). After 3 months, the biological
variation was again assessed by measuring
fasting blood samples at 4-day intervals
on 10 consecutive occasions. Duplicate
samples were randomized and then ana-
lyzed using a single batch (6,7). Serum
CRP was measured by the high-sensitivity
method on a Beckman DXC analyzer. The
intra-assay CV was 4% using the study
samples.
Statistical analysis
The distribution of hsCRP concentrations
within and between individuals is non-
Gaussian, so the Wilcoxon signed-rank
test was used to compare the median
hsCRP values of individual patients tak-
ing simvastatin compared with atorvasta-
tin. To compare the hsCRP variability
while on the statins, each hsCRP measure-
ment was log-transformed. Biological
variability of CRP on each drug was ana-
lyzed by calculating the analytical and
within-subject variability (8). The distri-
bution of these standard deviation (SDI)
values within the study population was
non-Gaussian, so the Wilcoxon signed-
rank test was used to compare the indi-
vidual SDs of patients when they were
taking each statin.
RESULTS— The baseline demograph-
ics, duration of diabetes, and glycemic
control were comparable in both groups
(9), as was the baseline hsCRP in patients
who were taking atorvastatin or simvasta-
tin initially (median [interquartile range]
1.18 [0.78–3.88] vs. 1.37 [0.70–5.21]
mg/l, P 0.52). LDL was comparable on
either treatment (atorvastatin 2.2  0.2
vs. 2.1  0.3 mmol/l [mean  SD], P 
0.19); however, the degree of lowering
with each statin was not assessed, since
the patients were already established on a
statin at study entry. One patient from
each group dropped out after completing
one arm because of poor compliance, one
patient withdrew because of developing
myalgia without any rise in creatinine ki-
nase when changed to simvastatin, and
another withdrew because of developing
lethargy on starting simvastatin.
The median hsCRP when taking ator-
vastatin was significantly lower than
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when the same patients took simvastatin
(median [interquartile range] 1.08 [0.70–
4.06] vs. 1.47 [0.87– 4.88] mg/l, P 
0.0002) (Fig. 1). The median hsCRP rose
significantly when patients who were ini-
tially taking atorvastatin were changed
over to simvastatin (1.18 [0.78–3.88] vs.
1.62 [1.03–5.01], P  0.0002), whereas
the median hsCRP fell after patients who
were initially taking simvastatin were
changed (1.37 [0.70 –5.21] vs. 1.04
[0.68–5.49], P 0.049). In 14 of 16 pa-
tients who changed from atorvastatin to
simvastatin, the hsCRP rose, and in 9 of
10 patients who changed from simvasta-
tin to atorvastatin, the hsCRP fell.
The variability of hsCRP was also
much lower when taking atorvastatin
compared with simvastatin (median [in-
terquartile range] of SD of logCRP 0.0036
[0–0.014] vs. 0.178 [0.091–0.280], P
0.0001) (Fig. 1). As with the median con-
centrations, the variability of hsCRP be-
came higher when changed from
atorvastatin to simvastatin (0.0053
[0–0.014] vs. 0.148 [0.110–0.200], P
0.002), with a change from simvastatin to
atorvastatin having the opposite effect
(0.210 [0.080 – 0.297] vs. 0.0069
[0–0.017], P  0.0052). In 15 of 16 pa-
tients who changed from atorvastatin to
simvastatin, their hsCRP variability in-
creased, and in 10 of 10 patients who
changed from simvastatin to atorvastatin,
the hsCRP fluctuations reduced.
CONCLUSIONS— Thi s s tudy
shows that among patients with type 2
diabetes, there is a greater reduction of
hsCRP with atorvastatin compared with
equivalent doses of simvastatin, even
though their lipid profiles were similar.
The variability of hsCRP was also less with
atorvastatin compared with simvastatin.
The best clinical outcomes for pa-
tients on statin treatment seem to occur
when there is a reduction in hsCRP in
addition to the reduction of LDL (3,4,10).
It is therefore hypothesized that among
very-high-risk patients undergoing statin
therapy, the dual goals of LDL and hsCRP
reduction should be considered a new
clinical target for therapy (2). From the
current study findings, it seems that pa-
tients are more likely to attain these two
goals if they are treated with atorvastatin
rather than simvastatin.
One of the features of hsCRP mea-
surement that complicates interpretation
of results is its wide intra-individual
variability (11,12). Our data have shown
that patients taking atorvastatin not only
had lower hsCRP concentrations, but had
markedly less biological variability than
when taking equivalent doses of
simvastatin. A single value on atorvastatin
treatment is therefore more likely to re-
flect the true hsCRP concentration of the
patient. However, the potential clinical
benefits of this reduced variability are less
clear than that of purely lowering average
hsCRP values.
Looking for existing evidence that
atorvastatin leads to fewer cardiovascular
events than simvastatin at the same de-
gree of LDL lowering is hampered by the
fact that most clinical trials involving the
two agents have deliberately aimed to
show a difference in LDL. Nonetheless, in
these comparative studies, event rates
have been more favorable with atorvasta-
tin in both randomized controlled studies
(13) and observational studies (14).
There was a significant deterioration of
median hsCRP and its variability when pa-
tients on atorvastatin were changed over to
simvastatin. On the other hand, median
hsCRP and its variability improved when
patients on simvastatin were changed over
to atorvastatin. The difference in variability
of hsCRP and direct LDL could be due to
the difference in stability of lipids while tak-
ing a relatively short half-life statin such as
simvastatin (2–3 h) compared with that of a
longer half-life statin such as atorvastatin
(24 h) (15). These changes may need to be
taken into account when considering
switching patients between the two statins
on any grounds.
In conclusion, an equivalent lipid-
lowering dose of atorvastatin improves
hsCRP as well as reduces the variability
compared with simvastatin in type 2 dia-
betic patients.
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